(19)
(11)EP 3 433 243 B8

(12)CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 B1)

(48)Corrigendum issued on:
13.10.2021 Bulletin 2021/41

(45)Mention of the grant of the patent:
08.09.2021 Bulletin 2021/36

(21)Application number: 17711673.8

(22)Date of filing:  21.03.2017
(51)International Patent Classification (IPC): 
C07D 401/12(2006.01)
A61P 25/28(2006.01)
A61K 31/4725(2006.01)
(52)Cooperative Patent Classification (CPC):
A61P 3/04; A61P 9/10; A61P 25/28; A61P 1/16; C07D 417/14; C07D 401/12; A61P 17/00; A61P 29/00; A61P 27/02
(86)International application number:
PCT/EP2017/056696
(87)International publication number:
WO 2017/162674 (28.09.2017 Gazette  2017/39)

(54)

NOVEL DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2

NEUARTIGE DERIVATE UND DEREN VERWENDUNG ALS SELEKTIVE CASPASE-2-INHIBITOREN

NOUVEAUX DÉRIVÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS SÉLECTIFS DE CASPASE-2


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 22.03.2016 EP 16305318

(43)Date of publication of application:
30.01.2019 Bulletin 2019/05

(73)Proprietors:
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
    75013 Paris (FR)
  • Université de Paris
    75006 Paris (FR)

(72)Inventor:
  • JACOTOT, Etienne
    75005 Paris (FR)

(74)Representative: Cousin, Geoffroy 
Fidal Innovation 4-6, avenue de l'Alsace
92400 Courbevoie
92400 Courbevoie (FR)


(56)References cited: : 
WO-A1-2014/026882
  
  • MICHEL C MAILLARD ET AL: "Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB , vol. 19, no. 19 16 August 2011 (2011-08-16), pages 5833-5851, XP002715860, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2011.08.020 Retrieved from the Internet: URL:http://www.sciencedirect.com/science/a rticle/pii/S0968089611006547 [retrieved on 2011-08-16] cited in the application
  • CHAUVIER ET AL.: "Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor", CELL DEATH AND DISEASE, vol. 2, no. e203, 2011, pages 1-11, XP002758421, cited in the application
  • POREBA ET AL.: "Small molecule active site directed tools for studying human caspases", CHEM. REV., vol. 115, 2015, pages 12546-12629, XP002758422, cited in the application
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).